Blab Tech
Grey Matters Health Secures First Brain-Dedicated PET Scanner for U.S. Clinic
Grey Matters Health Inc. announced on July 6 2026 that it has taken delivery of the first brain‑dedicated positron emission tomography (PET) scanner in the United States. The Canadian‑listed company, which trades on the Canadian Securities Exchange (CSE: GREY), Frankfurt Stock Exchange (FRANKFURT: AGW0), and OTC (OTC: AGNPF), will install the FDA‑cleared CareMiBrain™ system at its flagship NovaScan Neuroimaging Clinics™ site in Davie, Florida, on the campus of HCA Florida University Hospital.
The CareMiBrain™ platform is a standalone PET system that does not include an integrated computed tomography (CT) component. According to the company, the design cuts radiation exposure by roughly 25 % compared with conventional PET/CT scanners and features a chair‑style patient position that eliminates the need for patients to lie prone. The scanner is engineered for high‑resolution imaging of beta‑amyloid plaques, the hallmark of early Alzheimer’s disease (AD), and can also be employed for frontotemporal dementia, Parkinson’s disease, Lewy Body Dementia, and select neuro‑oncology studies.
Brain PET scans that detect beta‑amyloid are covered by Medicare, Medicaid, and private insurers for patients aged 65 and older. The new CareMiBrain system will enable clinicians to obtain the scans required for the recently FDA‑approved monoclonal‑antibody therapies Leqembi (Eisai/Biogen) and Kisunla (Eli Lilly). Both drugs mandate a positive beta‑amyloid PET scan or lumbar puncture before treatment can be authorized, creating a growing demand for dedicated brain PET imaging.
The market for beta‑amyloid imaging has expanded sharply since the approval of Leqembi and Kisunla, and industry analysts estimate a multi‑billion‑dollar opportunity for imaging providers that can deliver timely, high‑quality scans. Grey Matters Health’s focus on a dedicated brain PET platform is positioned to meet this demand, especially as the current supply of PET/CT scanners in the United States is largely allocated to oncology and cardiac imaging. About 45 % of PET/CT units are hospital‑based, and scheduling for brain‑specific studies is often delayed.
The Davie clinic will be the first U.S. location to offer a brain‑only PET service. Located in the HCA Florida University Medical Office Building, the facility will provide a patient‑centric experience, including the chair‑style scanner and streamlined workflow. According to the company, the clinic will also serve as a model for a planned network of similar neuroimaging centers across the country.
CEO Christopher J. Moreau called the scanner’s delivery a “tremendous milestone” and said the clinic would “offer the highest level of care possible to our patients, providing an improved diagnostic imaging experience that will reduce patient claustrophobia and dizziness through sitting instead of lying prone.” He added that the company is finalizing licensing, construction, and technical installation before announcing an official opening date and referral schedule.
Grey Matters Health remains in the preparatory phase for the Davie clinic, with the company stating that it will provide a subsequent update on the opening date and patient referral timelines. The company’s broader strategy involves expanding the NovaScan Neuroimaging Clinics™ network to address the growing need for early AD detection and other neurodegenerative disease diagnostics in the United States.
The announcement was issued through Globe Newswire and is supported by a press release dated July 6 2026. No additional regulatory filings or court actions have been reported at this time.
The CareMiBrain™ platform is a standalone PET system that does not include an integrated computed tomography (CT) component. According to the company, the design cuts radiation exposure by roughly 25 % compared with conventional PET/CT scanners and features a chair‑style patient position that eliminates the need for patients to lie prone. The scanner is engineered for high‑resolution imaging of beta‑amyloid plaques, the hallmark of early Alzheimer’s disease (AD), and can also be employed for frontotemporal dementia, Parkinson’s disease, Lewy Body Dementia, and select neuro‑oncology studies.
Brain PET scans that detect beta‑amyloid are covered by Medicare, Medicaid, and private insurers for patients aged 65 and older. The new CareMiBrain system will enable clinicians to obtain the scans required for the recently FDA‑approved monoclonal‑antibody therapies Leqembi (Eisai/Biogen) and Kisunla (Eli Lilly). Both drugs mandate a positive beta‑amyloid PET scan or lumbar puncture before treatment can be authorized, creating a growing demand for dedicated brain PET imaging.
The market for beta‑amyloid imaging has expanded sharply since the approval of Leqembi and Kisunla, and industry analysts estimate a multi‑billion‑dollar opportunity for imaging providers that can deliver timely, high‑quality scans. Grey Matters Health’s focus on a dedicated brain PET platform is positioned to meet this demand, especially as the current supply of PET/CT scanners in the United States is largely allocated to oncology and cardiac imaging. About 45 % of PET/CT units are hospital‑based, and scheduling for brain‑specific studies is often delayed.
The Davie clinic will be the first U.S. location to offer a brain‑only PET service. Located in the HCA Florida University Medical Office Building, the facility will provide a patient‑centric experience, including the chair‑style scanner and streamlined workflow. According to the company, the clinic will also serve as a model for a planned network of similar neuroimaging centers across the country.
CEO Christopher J. Moreau called the scanner’s delivery a “tremendous milestone” and said the clinic would “offer the highest level of care possible to our patients, providing an improved diagnostic imaging experience that will reduce patient claustrophobia and dizziness through sitting instead of lying prone.” He added that the company is finalizing licensing, construction, and technical installation before announcing an official opening date and referral schedule.
Grey Matters Health remains in the preparatory phase for the Davie clinic, with the company stating that it will provide a subsequent update on the opening date and patient referral timelines. The company’s broader strategy involves expanding the NovaScan Neuroimaging Clinics™ network to address the growing need for early AD detection and other neurodegenerative disease diagnostics in the United States.
The announcement was issued through Globe Newswire and is supported by a press release dated July 6 2026. No additional regulatory filings or court actions have been reported at this time.
